Abstract：
BACKGROUND: Laser ablation (LA) is a minimally invasive treatment. It has been widely used since the early 2000s to induce volume reduction of symptomatic benign thyroid nodules. Up to 40% of laser-treated nodules have been reported to achieve a volume reduction of <50% (technique inefficacy) at 12 months and tend to regrow over time.
OBJECTIVE: This study aimed to assess the optimal baseline volume and energy to be delivered to minimize technique inefficacy.
METHODS: This was a retrospective study. Data were collected, including baseline volume, energy delivered, and 12-month volume reduction ratio (VRR) of spongiform nodules (EU-TIRADS 2) treated with LA between 2010 and 2020. Based on these data, the optimal baseline volume and energy to be delivered were calculated to maximize the rate of nodules with technique efficacy (VRR ≥ 50% at 12-month follow-up).
RESULTS: A total of 205 patients with spongiform nodules were included in this study. The energy delivered was positively associated with VRR. However, no association was observed between baseline volume and VRR. Delivering energy ≥500 J/mL to nodules with a mean baseline volume of 11.4 ± 4 mL resulted in technique efficacy in 83% of cases.
CONCLUSIONS: Treating spongiform nodules with a baseline volume of ≤15 mL and delivering energy ≥500 J/mL are key factors for achieving a relevant rate of technique efficacy.
OBJECTIVE: This study aimed to assess the optimal baseline volume and energy to be delivered to minimize technique inefficacy.
METHODS: This was a retrospective study. Data were collected, including baseline volume, energy delivered, and 12-month volume reduction ratio (VRR) of spongiform nodules (EU-TIRADS 2) treated with LA between 2010 and 2020. Based on these data, the optimal baseline volume and energy to be delivered were calculated to maximize the rate of nodules with technique efficacy (VRR ≥ 50% at 12-month follow-up).
RESULTS: A total of 205 patients with spongiform nodules were included in this study. The energy delivered was positively associated with VRR. However, no association was observed between baseline volume and VRR. Delivering energy ≥500 J/mL to nodules with a mean baseline volume of 11.4 ± 4 mL resulted in technique efficacy in 83% of cases.
CONCLUSIONS: Treating spongiform nodules with a baseline volume of ≤15 mL and delivering energy ≥500 J/mL are key factors for achieving a relevant rate of technique efficacy.
摘要：
背景：激光消融（LA）是一种微创治疗方法。自2000年代初以来，它已被广泛用于诱导有症状的良性甲状腺结节的体积减少。据报道，多达40％的激光治疗结节在12个月时体积减少<50％（技术无效），并且随着时间的推移会重新生长。
目的：本研究旨在评估最佳的基线体积和能量，以最大程度地减少技术无效。
方法：这是一项回顾性研究。收集数据,包括基线体积，输送的能量，2010年至2020年间接受LA治疗的海绵状结节（EU-TIRADS2）的12个月体积减少率（VRR）。基于这些数据,计算最佳基线体积和能量,以最大限度地提高具有技术功效的结节发生率(12个月随访时VRR≥50%).
结果：本研究共纳入205例海绵状结节患者。传递的能量与VRR呈正相关。然而,基线体积和VRR之间未观察到相关性.向平均基线体积为11.4±4mL的结节提供≥500J/mL的能量导致83％的病例的技术疗效。
结论：治疗基线体积≤15mL的海绵状结节和输送能量≥500J/mL是获得相关技术疗效率的关键因素。
目的：本研究旨在评估最佳的基线体积和能量，以最大程度地减少技术无效。
方法：这是一项回顾性研究。收集数据,包括基线体积，输送的能量，2010年至2020年间接受LA治疗的海绵状结节（EU-TIRADS2）的12个月体积减少率（VRR）。基于这些数据,计算最佳基线体积和能量,以最大限度地提高具有技术功效的结节发生率(12个月随访时VRR≥50%).
结果：本研究共纳入205例海绵状结节患者。传递的能量与VRR呈正相关。然而,基线体积和VRR之间未观察到相关性.向平均基线体积为11.4±4mL的结节提供≥500J/mL的能量导致83％的病例的技术疗效。
结论：治疗基线体积≤15mL的海绵状结节和输送能量≥500J/mL是获得相关技术疗效率的关键因素。
